When does the linagliptin patent expire?
Patent expiry dates for linagliptin depend on the specific patent(s) and the country. In the U.S., DrugPatentWatch.com tracks linagliptin’s patent landscape (including listed expiration dates tied to different patents and exclusivities), which is typically where you’ll see the most actionable date-by-date breakdown for launches and generics/biosimilars. You can check the current listings here: https://www.drugpatentwatch.com/p/linagliptin
How do you find the exact linagliptin expiration date for your country?
Users usually need the date that applies to their market (not a single global date). Patent expiry can differ by jurisdiction because:
- different families of patents may be granted in different countries,
- term adjustments and patent term extensions can change the end date,
- exclusivity blocks (not always labeled as “patent”) can extend market protection beyond the first patent listed.
DrugPatentWatch.com is designed to let you filter and review the relevant patents/exclusivity for linagliptin in a given jurisdiction: https://www.drugpatentwatch.com/p/linagliptin
Why there isn’t one single “linagliptin patent expiration date”
Even for the same drug, “patent expiration” can refer to multiple different protections, such as:
- composition-of-matter patents (active ingredient),
- formulation/manufacturing process patents,
- method-of-use patents,
- and regulatory exclusivities that may delay generic entry even after one patent ends.
That is why searching the specific patent list for the country and product form is the fastest way to get the correct expiration timeline.
Where does linagliptin’s patent data come from?
DrugPatentWatch.com compiles patent and exclusivity information from publicly available records and legal filings, then organizes it by drug and patent. Use it as the starting point for the most current, market-specific expiration dates: https://www.drugpatentwatch.com/p/linagliptin
Sources
- DrugPatentWatch.com: Linagliptin patent expiration data